TransMedics Group (NASDAQ:TMDX) Now Covered by Evercore ISI

Key Points

• Evercore ISI has initiated coverage on TransMedics Group (NASDAQ:TMDX) with an "outperform" rating and a price target of $155.00, indicating a potential upside of 35.62% from its previous close.
• Analysts have a mixed outlook on the stock, with one Strong Buy, six Buy, and four Hold ratings, resulting in an average rating of "Moderate Buy" and a price target of $125.40.
• TransMedics Group recently reported an earnings per share of $0.92 for the last quarter, significantly exceeding analysts' expectations of $0.48, with revenue growing 37.7% year-over-year.

Analysts at Evercore ISI assumed coverage on shares of TransMedics Group (NASDAQ:TMDX - Get Free Report) in a report released on Tuesday, MarketBeat Ratings reports. The firm set an "outperform" rating and a $155.00 price target on the stock. Evercore ISI's price objective suggests a potential upside of 26.75% from the stock's current price.

Other equities analysts also recently issued reports about the company. Piper Sandler reiterated an "overweight" rating and set a $145.00 target price (up from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Canaccord Genuity Group raised their price target on TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday, July 15th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a report on Monday, August 25th. Wall Street Zen cut TransMedics Group from a "buy" rating to a "hold" rating in a report on Saturday, August 30th. Finally, Morgan Stanley raised their price target on TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a report on Friday, August 1st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $125.40.

TransMedics Group Stock Performance

Shares of TMDX stock traded up $1.19 on Tuesday, reaching $122.29. The stock had a trading volume of 2,097,343 shares, compared to its average volume of 957,407. The stock has a market cap of $4.17 billion, a P/E ratio of 63.36 and a beta of 2.18. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. The company has a 50 day simple moving average of $115.81 and a 200 day simple moving average of $106.93. TransMedics Group has a 1 year low of $55.00 and a 1 year high of $169.29.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.44. The company had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.TransMedics Group's quarterly revenue was up 37.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. Equities research analysts expect that TransMedics Group will post 1 EPS for the current year.

Institutional Investors Weigh In On TransMedics Group

Several large investors have recently made changes to their positions in TMDX. Cetera Investment Advisers increased its holdings in shares of TransMedics Group by 8.3% in the fourth quarter. Cetera Investment Advisers now owns 8,260 shares of the company's stock worth $515,000 after purchasing an additional 634 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in TransMedics Group by 6.2% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,657 shares of the company's stock worth $1,163,000 after acquiring an additional 1,096 shares during the last quarter. Nomura Holdings Inc. bought a new stake in TransMedics Group during the fourth quarter worth approximately $459,000. ProShare Advisors LLC increased its stake in TransMedics Group by 62.5% during the fourth quarter. ProShare Advisors LLC now owns 10,064 shares of the company's stock worth $627,000 after acquiring an additional 3,870 shares during the last quarter. Finally, Two Sigma Investments LP bought a new stake in TransMedics Group during the fourth quarter worth approximately $781,000. 99.67% of the stock is owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.